StockNews.com began coverage on shares of MacroGenics (NASDAQ:MGNX – Free Report) in a research note released on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also issued reports on MGNX. JMP Securities increased their price target on MacroGenics from $8.00 to $10.00 in […]